

Luis Colomo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/113174/publications.pdf>

Version: 2024-02-01

44
papers

2,043
citations

471509

17
h-index

377865

34
g-index

45
all docs

45
docs citations

45
times ranked

2726
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Blood</i> , 2011, 117, 4836-4843.	1.4	280
2	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. <i>Journal of Clinical Oncology</i> , 2005, 23, 2797-2804.	1.6	253
3	IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1686-1694.	3.7	251
4	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Haematologica</i> , 2013, 98, 1554-1562.	3.5	196
5	Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 958-963.	1.2	182
6	Primary Cutaneous Small/Medium CD4 ⁺ T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and Outcome. <i>Journal of Clinical Oncology</i> , 2008, 26, 3364-3371.	1.6	163
7	Nonhepatosplenic $\hat{3}$ T-cell Lymphomas Represent a Spectrum of Aggressive Cytotoxic T-cell Lymphomas With a Mainly Extranodal Presentation. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1214-1225.	3.7	120
8	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	3.5	100
9	Epstein-Barr Virus Negative Clonal Plasma Cell Proliferations and Lymphomas in Peripheral T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1310-1322.	3.7	77
10	HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. <i>Modern Pathology</i> , 2017, 30, 745-760.	5.5	60
11	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	1.4	53
12	SOX11 is useful in differentiating cyclin D1 ⁺ positive diffuse large B ⁺ cell lymphoma from mantle cell lymphoma. <i>Histopathology</i> , 2012, 61, 685-693.	2.9	41
13	Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 3754-3761.	7.0	31
14	Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. <i>Blood Advances</i> , 2020, 4, 5285-5296.	5.2	27
15	High <i>PTX3</i> expression is associated with a poor prognosis in diffuse large B ⁺ cell lymphoma. <i>Cancer Science</i> , 2022, 113, 334-348.	3.9	23
16	Diagnostic efficacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography in bone metastases of myxoid liposarcoma. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 625-628.	3.4	22
17	In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. <i>Modern Pathology</i> , 2014, 27, 1599-1611.	5.5	22
18	LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 877-886.	3.7	19

#	ARTICLE	IF	CITATIONS
19	Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. <i>British Journal of Haematology</i> , 2011, 153, 334-340.	2.5	18
20	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2019, 104, 778-788.	3.5	17
21	Novel phosphorylated TAK1 species with functional impact on NF- κ B and β -catenin signaling in human Cutaneous T-cell lymphoma. <i>Leukemia</i> , 2018, 32, 2211-2223.	7.2	14
22	Primary neuroendocrine small cell undifferentiated carcinoma of the parotid gland. <i>Clinical and Translational Oncology</i> , 2008, 10, 303-306.	2.4	13
23	Essential thrombocythaemia with mutation in <i>MPL</i> : clinicopathological correlation and comparison with <i>JAK2</i> V617F-mutated and <i>CALR</i> -mutated genotypes. <i>Journal of Clinical Pathology</i> , 2018, 71, 975-980.	2.0	12
24	Diagnosis of pleural malignant mesothelioma by EUS-guided FNA (with video). <i>Gastrointestinal Endoscopy</i> , 2008, 68, 1191-1193.	1.0	7
25	Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. <i>Blood Advances</i> , 2022, 6, 3921-3931.	5.2	7
26	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. <i>Blood Advances</i> , 2022, 6, 82-86.	5.2	6
27	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma. <i>Diagnostics</i> , 2022, 12, 1575.	2.6	6
28	Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. <i>Cancers</i> , 2020, 12, 884.	3.7	5
29	Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma With Secondary Cutaneous Involvement: A Diagnostic Challenge. <i>American Journal of Dermatopathology</i> , 2021, 43, 300-304.	0.6	5
30	No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 3615-3615.	1.4	5
31	Dissecting the <i>CD3⁺CD4⁺</i> T-cell population: A valuable screening tool for angioimmunoblastic T-cell lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 171-174.	1.5	2
32	Diagnostic Value of Genotypic Analysis in Primary Cutaneous Lymphomas using Standardized BIOMED-2 Polymerase Chain Reaction Protocols: Experience in Daily Clinical Practice. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00460.	1.3	1
33	Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, , 1.	2.8	1
34	T cell lymphoblastic lymphoma with uncommon CD20 expression. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 234-235.	1.3	1
35	Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine. <i>Frontiers in Immunology</i> , 2021, 12, 798251.	4.8	1
36	PCM1::JAK2 fusion associates with an atypical form of mycosis fungoides. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 967-973.	2.8	1

#	ARTICLE	IF	CITATIONS
37	Evaluation of routine CT scans in the follow-up of diffuse large B-cell lymphomas. Hematology, 2021, 26, 709-715.	1.5	0
38	Activation of the Endoplasmic Reticulum (ER) Unfolded Protein Response (UPR) in Aggressive B-Cell Lymphomas.. Blood, 2006, 108, 2038-2038.	1.4	0
39	Primary Extranodal Follicular Lymphoma: Clinicobiological Features and Outcome.. Blood, 2006, 108, 2456-2456.	1.4	0
40	T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.. Blood, 2009, 114, 1945-1945.	1.4	0
41	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	1.4	0
42	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134.	1.4	0
43	Abstract 2169: Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates their in vitro and in vivo activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma. , 2017, , .		0
44	Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas. Blood, 2019, 134, 2899-2899.	1.4	0